Episode 33: The Future of Synthetic Genomes with Codex DNA

The pandemic has influenced every company in every market. But companies that focus on synthetic DNA have been in a unique position to help. That's why Codex DNA has played, and continues to play, a crucial role in the fight against Covid-19. The creation and release of the world's first full-length synthetic genomes for the three Covid virus variants is a game-changer, not just for Covid but for the healthcare industry and the approach scientists will bring to future health crises. We sat down with Jason Lehmann, product marketing manager for Codex DNA to dive into how the genomes were created, how Codex DNA responded to the pandemic, and what the future of synthetic DNA will look like. Join us as we dive into this fascinating world and better understand the scientific community's approach to Covid.


Clara Mouawad

Clara is the Content Specialist at BCC Research, where she spends her time writing blogs and white papers, designing graphics and thinking up ways BCC can take over the world...like with a podcast.

A world traveler (less so during COVID19, of course), marketing whiz and always thirsty for knowledge, Clara finds innovators in a variety of fields and asks the question that our listeners want to know: How will this industry, technology or company shape how we live and work in the future?

Episode Timeline

  • [00:30]Introducing the world of synthetic genomes and Codex DNA
  • [01:55]Jason's story and what brought him to Codex DNA
  • [03:16]Codex DNA's mission and overview of what sets them apart
  • [05:13]The synthetic genomes for the 3 Covid-19 variants
  • [09:22]The process to creating the genomes and what sets Codex apart
  • [11:42]The impact that Covid-19 has had on Codex DNA
  • [14:05]The changes to vaccine and therapeutic development post pandemic
  • [18:00]What the BioXp 3250 system is and what it's capable of
  • [20:31]The future of synthetic biology in 10-15 years